Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Closed-loop systems and the artificial pancreas for T1DM recommendation released in Scotland

In January 2022, the Scottish Health Technology Group, SHTG, released a recommendation of the closed-loop systems and the artificial pancreas for type one diabetes mellitus (T1DM). A network meta-analysis and three pairwise meta-analyses found statistically significant improvements in mean percentage time in range for people with type one diabetes using a closed-loop system compared with other insulin-based therapies. The pairwise meta-analyses also reported statistically significant reductions in mean percentage time spent in hyperglycemia and hypoglycemia. High heterogeneity was present in all meta-analyses for all outcomes. The limited use of closed-loop systems in routine clinical care makes it difficult to estimate device-related adverse event rates.

The SHTG recommended that single hormone closed-loop systems should be available to people with type one diabetes (pediatric and adult) who:

  • Under their current diabetes care plan, continue to have suboptimal glycemic control, a high risk of severe hypoglycemia, or impaired awareness of hypoglycemia, or
  • Experience diabetes-related distress, measured using a validated tool, that adversely affects the quality of life or their ability to manage diabetes, and which is likely to be improved by moving to a closed-loop system.

No evidence was identified for artificial pancreas systems (multi-hormone closed-loop systems) available on the UK market.

Read more in English here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.